
AstraZeneca has signed an agreement to develop and commercialise a cancer nanomedicine from US firm Bind Therapeutics’ stable of Accurins. …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

